Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 1999

View Archived Issues

Scios signs drug screening and license agreement with Telik

Ares-Serono signs agreement with PowderJect for drug delivery system

Apotex extends agreement with Cangene

Preliminary results of testosterone replacement gel reported

Allelix clones GLP-2 receptor; advances development of ALX-0600

Preventive AIDS vaccine trial to begin in Thailand

Proteomics research grant awarded to Kinetek

New hemophilia treatment approved by Health Canada

Dainippon will initiate overseas trials of beta3 agonist

Yamanouchi, Ono establish codevelopment and marketing agreement for bisphosphonate

Zarix in-licenses oncology drug from Agouron

Another European market opens up to desirudin

Specific inhibitors of MEK for cancer and other proliferative disorders

New series of anticoagulants for oral administration developed at Lilly

More from SmithKline Beecham on p38 MAP kinase inhibitors

Patent covers new ADIR compounds with high affinity for imidazoline receptors

VUFB's phase III antirheumatic agent is available for licensing

Roche discloses inhibitors of TNF-alpha/TGF-alpha release, keratinocyte proliferation

First orally active, nonsteroidal androgen receptor agonist discovered at Ligand

CD-437, a novel retinoid compound targeted to the treatment of leukemia

Inhale branches out into pulmonary controlled release

AZT-cyclam/bicyclam prodrug conjugates designed at INSERM

Salix negotiates lafutidine license agreement with Fujirebio

FR-167653 compared to dexamethasone in acute lung inflammation

Wyeth-Ayerst seeks European approval of Rapamune

Amlodipine not associated with adverse arrhythmic events in CAD patients

CoCensys enters research agreements with Senju and Parke-Davis

Statins may be drugs of choice for adolescents with HeFH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...